PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsBimatoprost
Lumigan(bimatoprost)
Bimatoprost, Durysta, Ganfort, Latisse, Lumigan (bimatoprost) is a small molecule pharmaceutical. Bimatoprost was first approved as Lumigan on 2001-03-16. It is used to treat open-angle glaucoma in the USA. It has been approved in Europe to treat ocular hypertension and open-angle glaucoma. The pharmaceutical is active against prostaglandin F2-alpha receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
eye diseasesD005128
Trade Name
FDA
EMA
Bimatoprost, Durysta, Latisse, Lumigan (discontinued: Bimatoprost, Lumigan)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Bimatoprost
Tradename
Company
Number
Date
Products
LUMIGANAbbVieN-022184 RX2010-08-31
1 products, RLD, RS
DURYSTAAbbVieN-211911 RX2020-03-04
1 products, RLD, RS
LATISSEAbbVieN-022369 RX2008-12-24
1 products, RLD, RS
Show 1 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
bimatoprostANDA2025-01-02
durystaNew Drug Application2024-10-16
latisseNew Drug Application2024-07-01
lumiganNew Drug Application2024-06-20
morphine sulfateANDA2017-07-06
oxycodone hydrochlorideANDA2017-08-08
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
open-angle glaucomaEFO_0004190D005902H40.1
Agency Specific
FDA
EMA
Expiration
Code
BIMATOPROST, DURYSTA, ABBVIE
2023-03-04NP
Patent Expiration
Patent
Expires
Flag
FDA Information
Bimatoprost, Durysta, Abbvie
94923162034-10-31DP
99809742034-10-31U-2759
86291852031-07-15DS, DP
77993362029-04-24DP
82067372027-04-07U-2759
91494282026-12-19DP
104415432026-12-19DP
86733412025-02-19U-2759
103987072024-04-30U-2759
Bimatoprost, Lumigan, Abbvie
78515042027-06-13DS, DP
82783532025-03-16DP
82991182025-03-16U-1295
83096052025-03-16U-1293, U-1294
83384792025-03-16DPU-1295
85247772025-03-16U-1235
85866302025-03-16U-1458
87723382025-03-16DPU-1528
89331202025-03-16DP
89331272025-03-16DP
91557162025-03-16DPU-1528
92419182025-03-16DPU-1814
Bimatoprost, Latisse, Abbvie
81011612024-05-25U-1217, U-1218
80389882023-08-25DS, DPU-1208
82630542023-01-15U-1277
86327602023-01-15U-1487
87587332023-01-15U-1487
89867152023-01-15U-1217
92161832023-01-15U-1487
92269312023-01-15U-1799
ATC Codes
S: Sensory organ drugs
— S01: Ophthalmologicals
— S01E: Antiglaucoma preparations and miotics
— S01EE: Prostaglandin analogues, antiglaucoma drugs and miotics
— S01EE03: Bimatoprost
HCPCS
Code
Description
J7351
Injection, bimatoprost, intracameral implant, 1 microgram
Clinical
Clinical Trials
167 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Open-angle glaucomaD005902EFO_0004190H40.1114—16
HypertensionD006973EFO_0000537I10114——5
Ocular hypertensionD009798EFO_1001069H40.0114——5
GlaucomaD005901EFO_0000516H40114——5
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameBimatoprost
INNbimatoprost
Description
Bimatoprost is a monocarboxylic acid amide. It has a role as an antiglaucoma drug and an antihypertensive agent.
Classification
Small molecule
Drug classprostaglandins
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CCNC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)CCc1ccccc1
Identifiers
PDB—
CAS-ID155206-00-1
RxCUI—
ChEMBL IDCHEMBL1200963
ChEBI ID51230
PubChem CID5311027
DrugBankDB00905
UNII IDQXS94885MZ (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
AKR1C3
AKR1C3
Organism
Homo sapiens
Gene name
AKR1C3
Gene synonyms
DDH1, HSD17B5, KIAA0119, PGFS
NCBI Gene ID
8644
Protein name
aldo-keto reductase family 1 member C3
Protein synonyms
17-beta-HSD 5, 17-beta-hydroxysteroid dehydrogenase type 5, 3-alpha hydroxysteroid dehydrogenase, type II, 3-alpha-HSD type 2, 3-alpha-HSD type II, brain, 3-alpha-hydroxysteroid dehydrogenase type 2, Chlordecone reductase homolog HAKRb, DD-3, DD3, Dihydrodiol dehydrogenase 3, Dihydrodiol dehydrogenase type I, dihydrodiol dehydrogenase X, HA1753, indanol dehydrogenase, PGFS, Prostaglandin F synthase, Testosterone 17-beta-dehydrogenase 5, trans-1,2-dihydrobenzene-1,2-diol dehydrogenase, type IIb 3-alpha hydroxysteroid dehydrogenase
Uniprot ID
P42330
Mouse ortholog
—
—
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Bimatoprost
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 2,253 documents
View more details
Safety
Black-box Warning
Black-box warning for: Morphine sulfate, Oxycodone hydrochloride
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
21,983 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use